Capecitabine and the Bowel Battle: Addressing Diarrhea in Gastrointestinal Cancers - A Pakistan Perspective
DOI:
https://doi.org/10.36283/PJMD12-4/001Abstract
Cancer continues to be a global health challenge, and gastrointestinal malignancies significantly burden healthcare systems worldwide, including in Pakistan. Among the various treatment options available for gastrointestinal cancers, capecitabine, an oral chemotherapeutic agent, has shown promising results. However, its effectiveness comes with a potential side effect that poses a considerable challenge to both patients and healthcare providers - capecitabine-induced diarrhea. In the context of Pakistan's healthcare landscape, where access to specialized cancer care can be limited, addressing this issue becomes a critical aspect of ensuring better patient outcomes1.
Additional Files
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Pakistan Journal of Medicine and Dentistry
This work is licensed under a Creative Commons Attribution 4.0 International License.
This is an open-access article distributed under the terms of the CreativeCommons Attribution License (CC BY) 4.0 https://creativecommons.org/licenses/by/4.0/